Signed in as:
filler@godaddy.com
Enabling innovative cardiac cell therapy administered during cardiac surgery for heart failure treatment
CARDIAC CELL THERAPY IN SURGERY
CARDIAC CELL THERAPY IN SURGERY
CARDIAC CELL THERAPY IN SURGERY
EpiHeart is a University spin-off company leveraging over 10 years of dedicated research conducted on three continents. We are based in Helsinki, Finland, where we continue collaboration with University of Helsinki, Helsinki University Hospital "HUS" and Aalto University.
OUR FOCUS
CARDIAC CELL THERAPY IN SURGERY
CARDIAC CELL THERAPY IN SURGERY
EpiHeart is dedicated to enable new treatments that improve long term survival and quality of life of cardiac surgery patients. Our initial focus is in Cardiac Micrograft Therapy™. The pre-clinical and clinical results indicate positive effects on ventricular wall structure and scar size - critical factors contributing to heart failure.
COLLABORATION
CARDIAC CELL THERAPY IN SURGERY
COLLABORATION
EpiHeart is conducting clinical studies. We are open for collaboration with EU and US based cardiac surgery units and distributors. Our collaboration covers also research and commercial partnerships related to advanced cell and gene therapies that could be administered surgically.
SPARK Europe Showcase
EpiHeart was showcased among other upcoming startups and research-based innovation projects in SPARK Europe Showcase event in Birmingham, UK.
SATS Meeting 2024
EpiHeart participated to the annual meeting of the Scandinavian Association of Thoracic Surgery (SATS) in Gothenburg, Sweden. It was great to see Nordic cardiac surgeons and visit the thorax department at Sahlgrenska University Hospital. New ESC guidelines related to surgical closure of left atrial appendage were also discussed, read more by clicking button below.
EUMS-MAYO Congress 2024
EpiHeart's CEO Kai Kronström is presenting at 18th European Mechanical Circulatory Support Summit. Joint congress with Mayo Clinic is organized in Hannover, Germany.
2024 First Half Updates
The first efficacy study of Cardiac Micrograft Therapy using EpiHeart devices is ongoing and recruiting patients. In addition to the medical advances and making our first commercial sales, EpiHeart secured a funding in May 2024. Read more details by clicking the button below.
EpiHeart into collaboration with the University of Edinburgh
EpiHeart and the University of Edinburgh's Centre for Cardiovascular Science have entered into a collaboration to develop advanced cardiac cell therapy for the treatment of heart failure. The multi-year collaboration is supported by Medical Research Scotland.